Remission in schizophrenia: Results from a 1-year follow-up observational study

Schizophrenia Research

Volumn 108, Issue 1-3, 2009, Pages 214-222

  Ciudad, Antonio ^a   Álvarez, Enric ^b   Bobes, Julio ^c   San, Luis ^d   Polavieja, Pepa ^a   Gilaberte, Inmaculada ^a  

^a Medical Department   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSIDAD DE OVIEDO   (Spain)

^d Hospital de Igualada   (Spain)

Author keywords

Observational research; Outcome; Prevalence; Remission; Schizophrenia; Validation studies

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; CLINICAL ASSESSMENT; COGNITION; DEMOGRAPHY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REMISSION; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYMPTOM;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBSERVATION; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ADJUSTMENT; SPAIN;

EID: 60549086818     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.12.004     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (2000), American Psychiatric Association, Washington, DC.
2. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 39 (1982) 784-788
3. Andreasen N.C., Carpenter Jr. W.T., Kane J.M., Lasser R.A., Marder S.R., and Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 (2005) 441-449
4. Andreasen N.C., and Olsen S. Negative vs. positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry 39 (1982) 789-794
5. Barbui, C., Signoretti, A., Mule, S., Boso, M., Cipriani, A., in press. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr. Bull. (advance electronic access published on April 2008). doi:10.1093/schbul/sbn030.
6. Cannon-Spoor H.E., Potkin S.G., and Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 8 (1982) 470-484
7. Ciudad A., Prieto L., Olivares J.M., Montejo A.L., Ros S., Novick D., and Grupo Español del Estudio SOHO. The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample. Actas. Esp. Psiquiatr. 32 (2004) 227-235
8. Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., Leucht, S., in press. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. (advance electronic access published on April 2008). doi:10.1093/schbul/sbn018.
9. De Hert M.D., van Winkel R., Wampers M., Kane J., van Os J., and Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr. Res. 92 (2007) 68-73
10. Docherty J.P., Bossie C.A., Lachaux B., Bouhours P., Zhu Y., Lasser R., and Gharabawi G.M. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int. Clin. Psychopharmacol. 22 (2007) 51-55
11. Haas G.L., Garratt L.S., and Sweeney J.A. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J. Psychiatr. Res. 32 (1998) 151-159
12. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 28 Suppl 2 (2003) 17-54
13. Helldin L., Kane J.M., Karilampi U., Norlander T., and Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J. Psychiatr. Res. 40 (2006) 738-745
14. Helldin L., Kane J.M., Karilampi U., Norlander T., and Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr. Res. 93 (2007) 160-168
15. Hogan T.P., and Awad A.G. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol. Med. 22 (1992) 347-352
16. Lasser R.A., Bossie C.A., Gharabawi G.M., and Kane J.M. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 77 (2005) 215-227
17. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
18. Lindenmayer J.P., Grochowski S., and Hyman R.B. Five factor model of schizophrenia: replication across samples. Schizophr. Res. 14 (1995) 229-234
19. Luborsky L. Clinician's judgments of mental health. Arch. Gen. Psychiatry 7 (1962) 407-417
20. Malla A., Norman R., Schmitz N., Manchanda R., Bechard-Evans L., Takhar J., and Haricharan R. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol. Med. 36 (2006) 649-658
21. Norman R.M., Malla A.K., and Manchanda R. Early premorbid adjustment as a moderator of the impact of duration of untreated psychosis. Schizophr. Res. 95 (2007) 111-114
22. Opler M., Yang L., Caleo S., and Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 7 (2007) 35
23. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A., and Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 69 (2008) 106-113
24. Peuskens J., Kaufman L., and Van Vleymen B. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr. Res. 95 (2007) 169-173
25. Sanjuan J., Prieto L., Olivares J.M., Ros S., Montejo A., Ferrer F., Mayoral F., Gonzalez-Torres M.A., and Bousono M. GEOPTE Scale of social cognition for psychosis. Actas. Esp. Psiquiatr. 31 (2003) 120-128
26. Schmael C., Georgi A., Krumm B., Buerger C., Deschner M., Nothen M.M., Schulze T.G., and Rietschel M. Premorbid adjustment in schizophrenia-an important aspect of phenotype definition. Schizophr. Res. 92 (2007) 50-62
27. Strauss J.S., and Carpenter Jr. W.T. The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch. Gen. Psychiatry 31 (1974) 37-42
28. Torres A., and Olivares J.M. Validation of the Spanish version of the Social Functioning Scale. Actas. Esp. Psiquiatr. 33 (2005) 216-220
29. van Mastrigt S., and Addington J. Assessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale. J. Psychiatry Neurosci. 27 (2002) 92-101
30. van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., Bernardo M., Arango C., Fleischhacker W., Lachaux B., and Kane J.M. Standardized remission criteria in schizophrenia. Acta. Psychiatr. Scand. 113 (2006) 91-95
31. van Os J., Drukker M., à Campo J., Meijer J., Bak M., and Delespaul P. Validation of remission criteria for schizophrenia. Am. J. Psychiatry 163 (2006) 2000-2002
32. Ware Jr. J., Kosinski M., and Keller S.D. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 34 (1996) 220-233
33. Wunderink L., Nienhuis F.J., Sytema S., and Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr. Bull. 33 (2007) 792-796
34. Zimmerman M., Posternak M.A., and Chelminski I. Defining remission on the Montgomery-Asberg depression rating scale. J. Clin. Psychiatry 65 (2004) 163-168